COMPARATIVE EXPERIENCE OF COMBINED MEDICINE INTERFERON ALPHA-2b + BETAMETHASONE AND OLOPATADINE WITH MOMETHASONE IN THE TOPICAL TREATMENT OF POLLINOSIS EXACERBATIONS

DOI: https://doi.org/10.29296/25877305-2022-09-04
Issue: 
9
Year: 
2022

D. Trukhan(1), Dr Med. Sci.; V. Alekseenko(2); N. Kalashnikova(2); V. Minaeva(1);
O. Shelyapina(1), K. Nesterova(1), Dr Med. Sci.; N. Bagisheva(1), Cand. of Med. Sci.; Professor A. Mordyk(1), Dr Med. Sci.; V. Goloshubina(1), Cand. of Med. Sci.;
M. Moiseeva(1), Cand. of Med. Sci; O. Vins3; E. Nebesnaya(1),
1-Omsk State Medical University
2-Omsk City Polyclinic No. 12
3-Medical and Sanitary Department, Ministry of Internal Affairs of Russia, Omsk Region

Objective: To assess and compare the effectiveness and safety of the combined medicine interferon alpha-2b + betamethasone (Allergoferon® beta) and the combined use of olopatadine with mometasone furoate in the topical treatment of pollen allergy (pollinosis) exacerbations. Materials and methods. The study design was open, prospective, randomized and comparative. This study was conducted on the basis of the Department of Allergology and Immunology of the Omsk City Polyclinic No. 12. The study included 80 patients (men and women aged 20 to 64 years) who had consulted an allergist about moderate pollen allergy exacerbations. The patients were divided into two groups according to the treatment received: Group 1 (n=40) patients received olopatadine eye drops and mometazone nasal spray for the treatment of pollinosis; Group 2 (n=40) patients – the new combined medicine Allergoferon® beta in the form of eye and nasal drops. Patients’ conditions and the presence of moderate pollen allergy exacerbations were assessed at baseline (Visit 1, V1) and during follow-up examinations on the day 7 (Visit 2, V2) and day 14 (Visit 3, V3). Patients’ symptoms and signs were examined, which helped to determine the therapy effectiveness, the presence and severity of side effects. Tolerability of the given medicines was evaluated according to patients’ subjective assessment. Results. Control examinations of patients in both groups were conducted on the 7th and 14th days of treatment. On the 7th treatment day (V2) disappearance of nasal symptoms (rhinorrhoea – 0 points) was observed in 27,5% of group 1 patients and in 45% of group 2 patients. The resolution of ocular symptoms (itchy eyelids – 0 points) was observed in 17,5% and 30% of patients in groups 1 and 2 respectively. There was a reduction in the intensity of such symptoms as cough (in 18% and 20% of patients in groups 1 and 2 respectively) and sneezing (in 25% and 40% of patients in groups 1 and 2 respectively). After 14 treatment days (V3) disappearance of nasal symptoms (in particular nasal congestion – 0 points) was noted in 52.5% of group 1 patients and 62.5% of group 2 patients. Ocular symptoms (itchy eyelids – 0 points) resolved completely in 40% (group 1) and 52,5% (group 2) patients respectively. No lacrimation was observed in 57,5% (group 1) and 67,5% (group 2) patients. Cough and sneezing were resolved completely in 55% and 65% of group 2 (Allergoferon® beta) patients, by comparing with 45% and 53% of group 1 (olopatadine + mometazone) patients respectively. Conclusion. Following the study results and comparative assessment of the given medicines, it was revealed that the use of the combined medicine interferon alpha-2b + betamethasone (Allergoferon® beta) had higher effectiveness in the treatment of patients with moderate pollen allergy exacerbations as compared to the combination of olopatadine with mometazone. Patients noted a good tolerability of Allergoferon® beta (nasal and eye drops), convenience and ease of use. No side effects were observed during the use of this medicine. There were no cases of treatment withdrawal or refusal. The use of this new combined medicine in the treatment of pollen allergy (pollinosis) exacerbations helped to improve the patients’ quality of life and reduce the treatment time.
Keywords: 
pollinosis
pollen allergy
treatment
interferon alpha-2b + betamethasone
Allergoferon® beta
olopatadine
mometazone

References: 
  1. Puc M. Characterisation of pollen allergens. Ann Agric Environ Med. 2003; 10 (2): 143–9.
  2. Simon D. Recent advances in clinical allergy and immunology. Int Arch Allergy Immunol. 2018; 177 (4): 324–33. DOI: 10.1159/000494931
  3. De Weerd N., Bhalla P.L., Sing N.B. Aeroallergens and pjllinosis: molecular and immunological characteristics of cloned pollen allergens. Acrobiologia. 2002; 18: 87–106.
  4. Khoroshilova N.V. Blokatory N1-retseptorov k gistaminu v lechenii pollinozov. Meditsinskii vestnik. 2014; 19 (668) (in Russ.). URL: lib.medvestnik.ru/articles/Blokatory-N1-receptorov-k-gistaminu-v-lechenii-pollinozov.html
  5. Goryachkina L.A., Peredkova E.V., Astaf’eva N.G. Pollinozy. V kn.: Klinicheskaya allergologiya i immunologiya. Rukovodstvo dlya praktikuyushchikh vrachei. Pod red. L.A. Goryachkinoi, K.P. Kashkina. M.: Miklosh, 2009; s. 351–62 (in Russ.).
  6. Gushchin I.S., Kurbacheva O.M. Allergiya i allergenspetsificheskaya immunoterapiya. M.: Farmarus Print Media, 2010; 228 s. (in Russ.).
  7. Khaitov R.M., Il’ina N.I. Allergologiya i immunologiya: natsional’noe rukovodstvo. M.: GEOTAR-Media, 2009; 656 s. (in Russ.).
  8. Terekhova Ye.P., Nenasheva N.M., OSIPOVA G.L. et al. Pollinosis: the choice of antihistamine drug. Effektivnaya farmakoterapiya. 2019; 15 (15): 34–45 (in Russ.). DOI: 10.33978/2307-3586-2019-15-15-34-45
  9. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu allergicheskogo rinita. Rossiiskaya assotsiatsiya allergologov i klinicheskikh immunologov. M., 2013 (in Russ.).
  10. Nadey E.V., Nesterova K.I. Programming currents and severity of atopic allergic airway diseases. Omskii nauchnyi vestnik. 2014; 2 (134): 41–5 (in Russ.).
  11. D’Amato G., Cecchi L., Bonini S. et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007; 62 (9): 976–90. DOI: 10.1111/j.1398-9995.2007.01393.x
  12. Allergologiya i immunologiya. Natsional’noe rukovodstvo. Pod red. Z.M. Khaitova, N.I. Il’inoi. M.: GEOTAR-Media, 2009 (in Russ.).
  13. Nadey E.V., Nechaeva G.I., Sovalkin V.I. Nekotorye aspekty epidemiologii allergicheskikh zabolevanii v usloviyakh zapadnoi Sibiri. V sb.: Budushchee – za patsientorentirovannoi kardiologiei. Mat-ly VII s»ezda kardiologov Sibirskogo federal’nogo okruga sovmestno s VII Vseross. nauchno-prakt. konf. 2017; s. 96–7 (in Russ.).
  14. Goryachkina L.A., Drobik O.S., Nasunova A.Yu. Pollinozy: sovremennyi vzglyad na problemu. Vestnik semeinoi meditsiny. 2012; 1: 10–6 (in Russ.).
  15. Nadey E.V., Sovalkin V.I. The role of trigger factors in formation of allergy in Omsk region. Omskii nauchnyi vestnik. 2014; 2 (134): 37–40 (in Russ.).
  16. Knyazheskaya N.P., Potapova M.O., Yakovenko I.V. Pollinoz. Atmosfera. Pul’monologiya i allergologiya. 2005; 1: 2–4 (in Russ.).
  17. Nesterova K.I., Liapin V.A., Kazakovtsev V.P. et al. Local immunity of the nasal mucosa in healthy people of a large industrial center. Rossiiskii immunologicheskii zhurnal. 2015; 9 (1): 134–7 (in Russ.).
  18. Trukhan D.I., Filimonov S.N., Bagisheva N.V. Bolezni organov dykhaniya: aktual’nye aspekty diagnostiki i lecheniya. Novokuznetsk, 2020; 227 s. (in Russ.).
  19. Nesterova K.I., Nesterova A.A. Topicheskaya terapiya allergicheskogo rinita. V kn.: Mat-ly V Peterburgskogo foruma otorinolaringologov Rossii i IV vseross. kongr. po slukhovoi implantatsii s mezhdunar. uchast. 2016; s. 303–4 (in Russ.).
  20. Nadey E.V., Sovalkin V.I., Nesterova K.I. et al. Efficiency of combined anti-inflammatory therapy and allergenspecific immunotherapy of comorbidity allergic bronchial asthma: one-factor dispersion analysis. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018; 24 (3): 87–95 (in Russ.).
  21. Trukhan D.I., Bagisheva N.V., Alekseenko V.A. Actual aspects of diagnosis and treatment of atopic bronchial asthma. Therapy. 2017; 8 (18): 53–62 (in Russ.).
  22. Novoe slovo v lechenii allergicheskogo rinita. XIV Mezhdunarodnyi kongress «Sovremennye problemy immunologii, allergologii i immunofarmakologii» (in Russ.).
  23. Pfaar O., Agache I., de Blay F. et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. 2019; 74 (Suppl 108): 3–25. DOI: 10.1111/all.14077
  24. Sotnikova N.Yu. New perspectives in the treatment of allergic rhinitis and conjunctivitis: topical medications. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2017; 1: 42–50 (in Russ.).
  25. Nazarova E.V. New opportunities for the combined therapy of allergic rhinitis in real clinical practice. Rossiiskii allergologicheskii zhurnal. 2019; 1-1: 85–9 (in Russ.). DOI: 10.36691/RJA34
  26. Khmelevskoi V.I., Provotorov V.Ya., Kiseleva V.V. et al. Al’fa-interferon v klinicheskoi praktike. The Russian Archives of Internal Medicine. 2014; 5: 34–8 (in Russ.). DOI: 10.20514/2226-6704-2014-0-5-34-38
  27. Mashkova T.A., Mal’tsev A.B. Objective evaluation of the efficacy of mometasone furoate (nozefrin) in the treatment of polypoid rhinosinusitis. Russian Rhinology. 2018; 26 (4): 56–9 (in Russ.). DOI: 10.17116/rosrino20182604156
  28. Nenasheva N.M., Ilina N.I., Berdnikova N.G. Efficacy and safety of Momate Rhino (mometasone furoate nasal spray in the form of a metered) in adult patients with perennial allergic rhinitis: a randomized multicentre open clinical study. Consilium Medicum. 2016; 18 (11): 102–9 (in Russ.).
  29. Shabaldina E.V., Shabaldin A.V., Korostelev A.A. et al. The efficacy of topical therapy of allergic and non-allergic rhinitis in children with nozefriner (mometasone furoate). Rossiiskaya otorinolaringologiya. 2018; 4: 139–50 (in Russ.). DOI: 10.18692/1810-4800-2018-4-139-150
  30. Nesterova A.A., Drachuk A.I., Odarchenko I.N. et al. Allergoferon, kak preparat vybora v lechenii allergicheskogo rinita. V sb.: Nauchno-prakt. konf., posvyashch. 95-letiyu Omskoi oblastnoi klinicheskoi bol’nitsy. Sb. tr. konf. 2015; s. 356–7 (in Russ.).
  31. Strayer D.R., Carter W.A. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res. 2012; 32 (3): 95–102. DOI: 10.1089/jir.2011.0069
  32. Trukhan D., Alekseenko V., Kalashnikova N. et al. The use of combined recombinant interferon alpha-2b medications in the treatment of allergic rhinitis. Vrach. 2021; 32 (3): 73–81. (in Russ.). DOI: 10.29296/25877305-2021-03-13
  33. Ndika J., Airaksinen L., Suojalehto H. et al. Epithelial proteome profiling suggests the essential role of interferon-inducible proteins in patients with allergic rhinitis. J Allergy Clin Immunol. 2017; 140 (5): 1288–98. DOI: 10.1016/j.jaci.2017.05.040
  34. Zissler U.M., Schmidt-Weber C.B. Predicting Success of Allergen-Specific Immunotherapy. Front Immunol. 2020; 11: 1826. DOI: 10.3389/fimmu.2020.01826
  35. Scadding G.K. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Allergy. 2000; 55 (Suppl 62): 19–23. DOI: 10.1034/j.1398-9995.2000.055suppl62019.x
  36. Snyman J.R., Potter P.C., Groenewald M. et al.; Claricort Study Group. Effect of betamethasone-loratadine combination therapy on severe exacerbations of allergic rhinitis : a randomised, controlled trial. Clin Drug Investig. 2004; 24 (5): 265–74. DOI: 10.2165/00044011-200424050-00003
  37. Tillmann H.C., Stuck B.A., Feuring M. et al. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest. 2004; 34 (1): 67–73. DOI: 10.1111/j.1365-2362.2004.01293.x
  38. Mendoza de Morales T., Sánchez F. Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis. World Allergy Organ J. 2009; 2 (4): 49–53. DOI: 10.1097/WOX.0b013e31819f2105
  39. Trukhan L.I., Viktorova I.A. Bolezni organov dykhaniya. SPb: SpetsLit, 2013. 176 s. (in Russ.).
  40. Trukhan D.I., Filimonov S.N. Differentsial’nyi diagnoz osnovnykh pul’monologicheskikh simptomov i sindromov. SPb: SpetsLit, 2019; 176 s. (in Russ.).
  41. Ryabtseva A.A., Sotnikova N.Y., Chumikov O.V. et al. Efficacy and safety of a new combined medication with recombinant interferon and betamethasone in the treatment of hay fever during periods of exacerbation. Ophthalmology in Russia. 2016; 13 (3): 197–204 (in Russ.). DOI: 10.18008/1816-5095-2016-3-197-204
  42. Gonzales-van Horn S.R., Farrar J. D. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015; 98 (2): 185–94. DOI: 10.1189/jlb.3RU0315-099R
  43. Gaponyuk P.Ya. A new approach to the treatment of patients with allergic rhinitis. Allergologiya i immunologiya = Allergology and Immunology. 2008; 9: 277 (in Russ.).
  44. Trukhan D., Alekseenko V., Kalashnikova N. et al. Comparative experience of combined medicine interferon alpha-2b + betamethasone and azelastine in the treatment of pollinosis. Vrach. 2022; 33 (5): 68–77 (in Russ.). DOI: 10.29296/25877305-2022-05-15